John G. Kuhn

12.3k citations

188 papers · 8.8k indexed · h-index 55

Molecular Biology top 2%
Oncology top 0.5%
Genetics top 0.1%
Pulmonary and Respiratory Medicine top 1%
Cancer Research top 1%

Co-authors: Daniel D. Von Hoff Michael D. Prados Timothy F. Cloughesy Howard A. Burris Patrick Y. Wen Kathleen R. Lamborn Minesh P. Mehta Geoffrey R. Weiss
Topics: Glioma Diagnosis and Treatment (49 papers)Cancer Treatment and Pharmacology (44 papers)Cancer therapeutics and mechanisms (41 papers)
Cited by: Genetics Oncology Cancer Research
Journals: Journal of Clinical Oncology Blood JNCI Journal of the National Cancer Institute
Partner nations: United States Canada France

In The Last Decade

John G. Kuhn

186 papers receiving 8.5k citations

Peers

Countries citing papers authored by John G. Kuhn

Since Specialization

Citations

This map shows the geographic impact of John G. Kuhn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John G. Kuhn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John G. Kuhn more than expected).

Fields of papers citing papers by John G. Kuhn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John G. Kuhn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John G. Kuhn. The network helps show where John G. Kuhn may publish in the future.

Co-authorship network of co-authors of John G. Kuhn

This figure shows the co-authorship network connecting the top 25 collaborators of John G. Kuhn. A scholar is included among the top collaborators of John G. Kuhn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John G. Kuhn. John G. Kuhn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study) 2019 ·Breast Cancer Research ·Tejal Patel,Joe Ensor,(unknown),(unknown),Angel Rodriguez,(unknown),Jorge Darcourt,Jane Meisel,Xiaoxian Li,Jing Zhao,John G. Kuhn,Roberto R. Rosato,Wei Qian,Anna Belcheva,Mary R. Schwartz,Virginia Kaklamani,Jenny C. Chang	48
2	Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer 2018 ·Clinical Cancer Research ·Daniel Dávila‐González,Dong Soon Choi,Roberto R. Rosato,Sergio Granados‐Principal,John G. Kuhn,Wenfeng Li,Wei Qian,Wen Chen,Anthony J. Kozielski,Helen Wong,Bhuvanesh Dave,Jenny C. Chang	68
3	A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier 2018 ·Pharmaceutics ·(unknown),Zachary N. Warnken,Yajie Zhang,Daniel A. Davis,Hugh D. C. Smyth,John G. Kuhn,Steve Weitman,Robert O. Williams	23
4	Personalized Medicine in Nasal Delivery: The Use of Patient-Specific Administration Parameters To Improve Nasal Drug Targeting Using 3D-Printed Nasal Replica Casts 2018 ·Molecular Pharmaceutics ·Zachary N. Warnken,Hugh D. C. Smyth,Daniel A. Davis,Steve Weitman,John G. Kuhn,Robert O. Williams	66
5	A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab 2017 ·British Journal of Haematology ·Ahmed Sawas,Charles M. Farber,Marshall T. Schreeder,(unknown),Daruka Mahadevan,Changchun Deng,Jennifer E. Amengual,Petros Nikolinakos,Jill Kolesar,John G. Kuhn,Peter Sportelli,Hari P. Miskin,Owen A. O’Connor	61
6	Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes 2016 ·Cancer Prevention Research ·Chen-Pin Wang,Donna M. Lehman,(unknown),John G. Kuhn,Devalingam Mahalingam,Steven Weitman,Carlos Lorenzo,John R. Downs,Elizabeth A. Stuart,Javier Hernández,Ian M. Thompson,Amelie G. Ramírez	20
7	Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies 2016 ·Clinical Cancer Research ·Kevin R. Kelly,(unknown),Avvaru N. Suhasini,An-Ping Lin,John G. Kuhn,Anand B. Karnad,Steven Weitman,Ricardo C.T. Aguiar	27
8	Toward precision medicine in glioblastoma: the promise and the challenges 2015 ·Neuro-Oncology ·Michael D. Prados,Sara A. Byron,Nhan L. Tran,Joanna J. Phillips,Annette M. Molinaro,Keith L. Ligon,Patrick Y. Wen,John G. Kuhn,Ingo K. Mellinghoff,John de Groot,Howard Colman,Timothy F. Cloughesy,Susan M. Chang,Timothy C. Ryken,Waibhav Tembe,Jeffrey Kiefer,Michael E. Berens,David W. Craig,John D. Carpten,Jeffrey M. Trent	157
9	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03 2011 ·Neuro-Oncology ·Fábio M. Iwamoto,Kathleen R. Lamborn,John G. Kuhn,Patrick Y. Wen,W.K. Alfred Yung,Mark R. Gilbert,Susan M. Chang,Frank S. Lieberman,Michael D. Prados,Howard A. Fine	94
10	A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1 2006 ·Neuro-Oncology ·Michael D. Prados,Kathleen R. Lamborn,W. K. Alfred Yung,Kurt A. Jaeckle,H. Ian Robins,Minesh P. Mehta,Howard A. Fine,Patrick Y. Wen,Timothy F. Cloughesy,Susan M. Chang,M. Kelly Nicholas,David Schiff,Harry S. Greenberg,Larry Junck,Karen Fink,Ken Hess,John G. Kuhn	187
11	Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 2005 ·Clinical Cancer Research ·Andrew B. Lassman,Michael R. Rossi,(unknown),Lauren E. Abrey,Frank S. Lieberman,(unknown),Kathleen R. Lamborn,William Pao,Alan H. Shih,John G. Kuhn,Richard K. Wilson,Norma J. Nowak,John K. Cowell,Lisa M. DeAngelis,Patrick Y. Wen,Mark R. Gilbert,Susan M. Chang,WK Alfred Yung,Michael D. Prados,Eric C. Holland	201
12	A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer 2005 ·Annals of Oncology ·Monica Mita,(unknown),Eric K. Rowinsky,John G. Kuhn,Garry Schwartz,L. A. Hammond,Amita Patnaik,I‐Tien Yeh,Elżbieta Izbicka,(unknown),Anthony W. Tolcher	36
13	Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks 2001 ·Annals of Oncology ·Mace L. Rothenberg,John G. Kuhn,Larry J. Schaaf,G I Rodriguez,S. Gail Eckhardt,Miguel A. Villalona‐Calero,David Rinaldi,L. A. Hammond,(unknown),Anusha Sharma,Gary Elfring,(unknown),Paula K. Locker,L.L. Miller,Daniel D. Von Hoff	32
14	Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study 2001 ·Melanoma Research ·Seth P. Harlow,David N. Krag,Takashi Ashikaga,Donald L. Weaver,Sybren Meijer,Brian W. Loggie,Kenneth K. Tanabe,Pat W. Whitworth,John G. Kuhn,Roberto E. Kusminsky,Ned Z. Carp,Michelle A. Gadd,Maurice S. Rawlings,Craig L. Slingluff	63
15	Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion 1994 ·Anti-Cancer Drugs ·Howard A. Burris,Ahmad Awada,John G. Kuhn,John R. Eckardt,Patrick Cobb,(unknown),(unknown),Lon Smith,Daniel D. Von Hoff	40
16	Activity of DMP 840, a New Bis-naphthalimide, on Primary Human Tumor Colony-Forming Units 1994 ·JNCI Journal of the National Cancer Institute ·Patrick Cobb,Donna Degen,Gary M. Clark,(unknown),John G. Kuhn,J. Gross,(unknown),Jin-Hua Sun,Howard A. Burris,Daniel D. Von Hoff	13
17	Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. 1993 ·Journal of Clinical Oncology ·Howard A. Burris,(unknown),John G. Kuhn,(unknown),Lee Smith,Don W. Shaffer,Suzanne M. Fields,Geoffrey R. Weiss,John R. Eckardt,Gladys Rodriguez	120
18	A phase I trial of trimetrexate (NSC352122) on a daily × 5 schedule in patients with refractory adult leukemia 1993 ·Anti-Cancer Drugs ·Gladys Rodriguez,Thomas D. Brown,Frank M. Balis,John B. Craig,Claude Denham,John G. Kuhn,Kathleen A. Havlin,Daniel D. Von Hoff	3
19	Phase I evaluation of 773U82 HCI, a member of a new class of DNA intercalators 1991 ·Anti-Cancer Drugs ·Kathleen A. Havlin,John G. Kuhn,John B. Craig,Geoffrey R. Weiss,Jim M. Koeller,(unknown),Jay Luther,(unknown),Kenneth W. Bair,William A. Wargin,Virginie Lucas,(unknown),Daniel D. Von Hoff	0
20	Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule. 1988 ·PubMed ·(unknown),John B. Craig,John G. Kuhn,Jay Luther,(unknown),Geoffrey R. Weiss,(unknown),Jim M. Koeller,Richard L. Tuttle,Virginie Lucas	12

About John G. Kuhn

John G. Kuhn is a scholar working on Genetics, Oncology and Cancer Research, having authored 188 papers that have together received 8.8k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (49 papers), Cancer Treatment and Pharmacology (44 papers) and Cancer therapeutics and mechanisms (41 papers). The work is most often cited by research in Genetics (2.9k citations), Oncology (3.4k citations) and Cancer Research (1.4k citations). John G. Kuhn has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Daniel D. Von Hoff, Michael D. Prados, Timothy F. Cloughesy, Howard A. Burris, Patrick Y. Wen, Kathleen R. Lamborn, Minesh P. Mehta, Geoffrey R. Weiss, Susan M. Chang and H. Ian Robins. Their work appears in journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact